Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hematologic Diseases

• Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
• RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
• Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
• CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
• Allo HSCT Using RIC and PTCy for Hematological Diseases
• Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
• Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
• CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
• A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (ANV419-102).
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are L
• A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma.
• Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
• Itacitinib for the Prevention of Graft Versus Host Disease
• Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
• CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
• Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
• Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant
• PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
• PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
• Safety and Tolerability Evaluation of MaaT033
• Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
• AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
• Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
• XIENCE 28 USA Study
• TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
• XIENCE 28 Global Study
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
• Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
• A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
• Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
• A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
• Umbilical Cord Blood Transplantation From Unrelated Donors
• Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)
• CMV-CTL for the Treatment of CMV Infection After HSCT
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
• Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
• Allo HSCT Using RIC for Hematological Diseases
• URMC Related Haplo-identical Donor BMT
• Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
• A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.
• Prospective Study of Patients With Thrombocytopenia Following HSCT
• Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
• Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
• Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
• Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
• A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
• Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
• Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
• Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
• Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
• Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
• Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
• Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
• Dexamethasone Dyspnea Study
• Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
• Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
• Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.
• A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
• Steroid Treatment for Hypereosinophilic Syndrome
• The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
• Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
• Ultra Low Dose Interleukin-2 in Healthy Volunteers
• Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital
• Cord Blood Transplantation for Patients With Cancer
• SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
• Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
• Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders
• Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
• Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
• Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
• Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters
• Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
• Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
• Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
• Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
• Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
• Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation
• Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
• Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
• Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
• ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding
• BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
• Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
• Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
• A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
• Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
• Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
• Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
• Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
• A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
• A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
• T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
• Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
• Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
• Stroke With Transfusions Changing to Hydroxyurea
• Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease
• SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
• Treatment and Management of Women With Bleeding Disorders
• Stem Cell Transplant for Hematologic Diseases
• Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
• Induction of Stable Chimerism for Sickle Cell Anemia
• Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
• Blood and Marrow Transplant Clinical Research Network
• Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
• Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
• A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome
• Medical Treatment for Diamond Blackfan Anemia
• Comparing Therapies for the Treatment of Severe Aplastic Anemia
• A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
• Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
• Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
• Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
• Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
• Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
• Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
• Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
• Cooperative Study of Factor VIII Inhibitors